New Wave Biotech
AI bioprocess simulation and optimization software for scaling fermentation-based products.
Website: https://www.newwavebiotech.com
Cover Block
PUBLIC
| Attribute | Value |
|---|---|
| Company | New Wave Biotech |
| Tagline | AI bioprocess simulation and optimization software for scaling fermentation-based products. |
| Headquarters | London, UK |
| Founded | 2022 |
| Stage | Seed |
| Business Model | SaaS |
| Industry | Deeptech |
| Technology | AI / Machine Learning |
| Geography | Western Europe |
| Growth Profile | Venture Scale |
| Founding Team | Solo Founder |
| Funding Label | Seed (total disclosed ~$1,320,000) |
Links
PUBLIC
- Website: https://www.newwavebiotech.com/
- LinkedIn: https://uk.linkedin.com/company/new-wave-biotech
Data Accuracy: GREEN -- Confirmed by company website and LinkedIn company page.
Executive Summary
PUBLIC
New Wave Biotech sells AI simulation software to de‑risk and accelerate the scaling of fermentation‑based products, a critical bottleneck for alternative protein and synthetic biology manufacturers aiming for commercial viability [Dealroom, retrieved 2026]. Founded in 2022, the company emerged to address the costly and time‑intensive downstream processing (DSP) stage, where purification and separation can stall scale‑up. Its core product, Bioprocess Foresight, models purification workflows, runs virtual experiments, and provides integrated techno‑economic analysis to help customers improve yields and reduce wet‑lab experimentation [New Wave Biotech, retrieved 2026].
The founding team is led by CEO Zoe Yu Tung Law, whose public profile centers on articulating the company's technical vision and market positioning [AI Market Watch, Oct 2024]. Co‑founder Oli Hall is identified as CTO, though detailed prior professional backgrounds for both are not extensively documented in public sources [The Org, retrieved 2026]. The company has secured approximately €1.2 million in a late‑2024 funding round, a mix of grant and equity capital from mission‑aligned backers including EIT Food and Innovate UK [EU‑Startups, Dec 2024]. Revenue is generated through software licensing and services, targeting synbio innovators developing alternative proteins, biochemicals, and biomaterials.
Over the next 12‑18 months, the key watchpoints are the translation of reported performance improvements,such as an 8.6x yield gain cited in partner case studies,into named customer traction and recurring revenue, and the company's ability to defend its focused DSP wedge as broader bioprocess optimization and AI‑for‑science competitors enter the space.
Data Accuracy: YELLOW -- Core product and funding details are confirmed; team backgrounds and commercial traction are less documented.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Stage | Seed |
| Business Model | SaaS |
| Industry / Vertical | Deeptech |
| Technology Type | AI / Machine Learning |
| Geography | Western Europe |
| Growth Profile | Venture Scale |
| Founding Team | Solo Founder |
| Funding | Seed (total disclosed ~$1,320,000) |
Company Overview
PUBLIC
New Wave Biotech was founded in 2022, emerging from the UK's synthetic biology ecosystem with a focus on a specific and costly bottleneck in biomanufacturing. The company's origin story centers on applying computational modeling to downstream processing, the purification stage of fermentation, which is widely recognized as a major hurdle for scaling alternative proteins and other bio-based products [Dealroom, retrieved 2026]. The founding team, led by CEO Zoe Yu Tung Law, established the company to provide virtual simulation tools aimed at reducing the time and capital required for wet-lab experimentation during process development [New Wave Biotech, retrieved 2026].
Headquartered in London, the company's early trajectory has been shaped by participation in several prominent European climate and food-tech accelerators. Key milestones include acceptance into the Tech Nation Climate Programme and the EIT Food Accelerator Network, which provided initial non-dilutive funding and validation [CB Insights, retrieved 2026]. This was followed by support from the New Protein Accelerator Program and an investment from Big Idea Ventures, aligning the company with specialized investors in the alternative protein space [CB Insights, retrieved 2026].
The most significant disclosed capital event to date is a €1.2 million (estimated $1.26 million) funding round secured in late 2024. This round, characterized as a mix of equity and grant funding, involved lead backers EIT Food and Innovate UK, alongside continued participation from Big Idea Ventures [EU-Startups, Dec 2024]. The capital is earmarked for advancing the company's core AI bioprocess simulation platform and expanding its commercial reach [EU-Startups, Dec 2024].
Data Accuracy: GREEN -- Founding year and headquarters confirmed by Dealroom and Crunchbase. Accelerator participation and the 2024 funding round are corroborated by CB Insights and EU-Startups.
Product and Technology
MIXED The company’s core proposition is a software platform that applies computational modeling to a specific, costly phase of biomanufacturing. New Wave Biotech develops AI-driven simulation and optimization software focused exclusively on downstream processing (DSP) for fermentation-based products, a stage encompassing purification, separation, and recovery [Dealroom, retrieved 2026]. Its platform, branded as 'Bioprocess Foresight,' runs virtual experiments to model purification operations and suggests optimal process configurations, aiming to reduce the need for physical wet-lab trials [New Wave Biotech, retrieved 2026]. The software integrates techno-economic analysis and life cycle assessment, providing a decision-support layer for biomanufacturing teams scaling alternative proteins, biochemicals, and biomaterials [New Wave Biotech, retrieved 2026].
The public differentiation rests on this narrow focus on DSP, a recognized scaling bottleneck, and the integration of sustainability metrics. The company claims its technology has delivered results including an 8.6x improvement in yields and a 55% reduction in unit costs for partners, alongside a 92% reduction in required experiments [Green Queen, retrieved 2026]. These performance claims, while prominently featured in secondary press, originate from 'previous projects' and lack independent, public validation; they are not accompanied by named customer case studies or detailed methodology. The business model is software licensing and services [Dealroom, retrieved 2026].
Technical stack details are not disclosed, but job postings for Full Stack and Back-End Developer roles suggest a cloud-based application built with modern web frameworks (inferred from job postings) [New Wave Biotech, retrieved 2026]. The platform’s reliance on proprietary computational models and machine learning for simulation is stated, but the underlying algorithms, data sources, and validation benchmarks remain [PRIVATE]. No public roadmap for new product surfaces or features has been announced.
Data Accuracy: YELLOW -- Product claims are sourced from the company website and secondary press; performance metrics are uncorroborated. Technical stack is inferred.
Market Research
PUBLIC
New Wave Biotech's market is defined by a single, acute bottleneck: the high cost and slow pace of scaling fermentation-based products from lab to commercial production, a problem that has attracted significant venture capital and government funding to the synthetic biology sector.
The company targets innovators in alternative proteins, biochemicals, and biomaterials who rely on precision fermentation [Dealroom, retrieved 2026][GFI, retrieved 2026]. The total addressable market for the broader synthetic biology tools and enabling technologies sector is substantial, though direct sizing for downstream process (DSP) optimization software is not publicly available in cited sources. For context, the global market for bioprocess analytical technology, a related field, was valued at $2.8 billion in 2022 and is projected to grow at a compound annual rate of 13.5% through 2030 (analogous market, Grand View Research).
Demand is driven by the push for cost parity in alternative proteins and the capital intensity of biomanufacturing scale-up. Wet-lab experiments for process development are time-consuming and expensive, creating a clear economic incentive for virtual simulation tools that can reduce physical trial counts [New Wave Biotech, retrieved 2026]. Tailwinds include sustained public and private investment in sustainable supply chains, with entities like the European Union's EIT Food and the UK's Innovate UK actively funding technology to de-risk bioproduction [EU-Startups, Dec 2024].
Key adjacent markets include upstream fermentation optimization and broader process analytical technology (PAT), which are often addressed by larger industrial automation and life science tooling companies. Regulatory forces are generally favorable, with policies in Europe and North America increasingly supporting bio-based and circular economies, though specific compliance requirements for software used in process validation remain a consideration for enterprise adoption.
| Metric | Value |
|---|---|
| Bioprocess Analytical Tech (2022) | 2.8 $B |
| Projected Growth Rate (to 2030) | 13.5 % CAGR |
The chart illustrates the growth trajectory of the adjacent bioprocess analytical technology sector, suggesting a receptive and expanding environment for software that improves manufacturing efficiency. While not a direct measure of New Wave's niche, it indicates the scale of investment flowing into tools that make bioproduction more predictable and economical.
Data Accuracy: YELLOW -- Market sizing is inferred from an analogous sector report; specific TAM for DSP simulation software is not confirmed by primary company sources.
Competitive Landscape
MIXED New Wave Biotech's competitive position is defined by its narrow focus on downstream processing for fermentation, a specific bottleneck that broader simulation platforms often treat as a secondary module.
Given the absence of directly named competitors in the structured sources, a formal comparison table cannot be constructed. The analysis proceeds by mapping the adjacent landscape.
The competitive map for bioprocess software is fragmented by scope. At the broadest level, incumbent process simulation giants like AspenTech (Aspen Plus) and Siemens (Simcenter) offer mature, general-purpose chemical engineering suites. These are deeply embedded in traditional pharma and chemicals but are not optimized for the unique unit operations and economic drivers of novel fermentation-based products like alternative proteins [Dealroom]. A second segment includes modern, cloud-native bioprocess platforms. Companies like Synthace (now part of Dassault Systèmes) and Benchling provide digital R&D workbenches with strong upstream design and data management capabilities, but their downstream purification optimization is typically less developed. New Wave's wedge is to own the DSP layer entirely, providing integrated techno-economic and sustainability analysis specifically for scaling bio-manufacturing [New Wave Biotech].
Its defensible edge today rests on two pillars: technical focus and early ecosystem alignment. By concentrating solely on DSP, the company can develop deeper, more applicable models for filtration, chromatography, and centrifugation in a bio-context than generalists. This focus is reinforced by participation in accelerator programs like EIT Food and the New Protein Accelerator, which provide direct access to its target customer base of synbio startups [CB Insights]. This early-mover network effect is perishable, however, if it fails to convert pilot projects into entrenched, scaled deployments before well-funded incumbents or new entrants decide to build or acquire similar dedicated capabilities.
The company's primary exposure is not to a named direct competitor, but to the strategic roadmap decisions of the broader platform players. If a company like Benchling or a computational biology tool such as Ginkgo Bioworks' foundry software decides to build a robust, in-house DSP simulation module, it could bundle that functionality into a larger suite, undermining New Wave's standalone value proposition. Furthermore, the company's reliance on grant and non-dilutive funding from entities like Innovate UK, while advantageous for capital efficiency, may signal a commercial traction timeline that is not yet proven against venture-scale expectations [EU-Startups, Dec 2024].
The most plausible 18-month scenario hinges on market education and partnership strategy. The winner will be the entity that most effectively convinces bio-manufacturing teams that DSP optimization is a critical, standalone software category worthy of dedicated spend. If New Wave can use its accelerator connections to secure design wins with several leading alternative protein companies, it could establish a reference architecture that becomes the industry standard. Conversely, the loser would be a company that remains a niche consulting service masked as a software platform; if New Wave's "Bioprocess Foresight" tool cannot demonstrate clear, repeatable ROI and transition to a scalable SaaS model, it risks being sidelined as a feature within a larger competitor's offering.
PUBLIC If New Wave Biotech can translate its simulation-driven efficiency gains into a standard workflow for scaling fermentation, the company could capture a pivotal, high-margin layer in the multi-billion dollar synthetic biology infrastructure stack.
The headline opportunity is to become the default simulation and decision-support layer for downstream bioprocess development, a role analogous to what Cadence or Ansys provides in semiconductor design. The company's focus on downstream processing (DSP) targets a well-documented bottleneck; scaling fermentation-based products is often hindered by costly, iterative purification and separation steps [Dealroom, retrieved 2026]. By providing a software suite that reduces the need for physical experiments, New Wave Biotech is positioning itself not just as a tool vendor but as a critical path enabler for commercializing alternative proteins and biochemicals. The cited traction from accelerator programs like EIT Food and Big Idea Ventures suggests the core thesis,that virtual experimentation saves significant time and capital,is resonating with key stakeholders in the target market [EU-Startups, Dec 2024].
Growth from this early wedge could follow several distinct, concrete paths.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| DSP Platform Standard | The software becomes a mandated, embedded part of the R&D workflow for major synbio producers and CDMOs. | A public, multi-year partnership with a leading alternative protein company (e.g., Perfect Day, The EVERY Co.) to co-develop and validate models. | The company's explicit focus on DSP for fermentation aligns with a critical scaling pain point acknowledged across the industry [GFI, retrieved 2026]. Early grant and accelerator support from domain-specific investors like EIT Food provides a network to pursue such partnerships. |
| Regulatory & Sustainability Data Hub | The platform's integrated life cycle assessment (LCA) module becomes the primary source for environmental impact data required for product labeling and regulatory filings. | A major food or chemical conglomerate adopts the tool to streamline sustainability reporting for its new bio-based product lines. | New Wave Biotech's product description explicitly includes "integrated techno-economic analysis and life cycle assessment" as a core feature, directly addressing growing corporate and regulatory demands for sustainability metrics [New Wave Biotech, retrieved 2026]. |
Compounding in this model would be driven by a data and workflow flywheel. Each new customer's process data, when anonymized and aggregated, could improve the accuracy and predictive power of the underlying simulation models. This creates a classic data network effect: a better-trained platform attracts more customers, whose usage further refines the models. Early evidence of this dynamic is not yet publicly visible in customer case studies, but the company's active hiring for backend and full-stack developer roles suggests a focus on scaling the core technology and data infrastructure [New Wave Biotech, retrieved 2026].
The size of the win, should the platform standard scenario materialize, can be framed by looking at comparable infrastructure software providers in adjacent deep-tech fields. For instance, publicly traded simulation software companies serving capital-intensive R&D sectors, like ANSYS or Dassault Systèmes, command enterprise values that are multiples of their revenue, reflecting the high strategic value and gross margins of their products. While New Wave Biotech is at a seed stage, a plausible outcome for a category-defining DSP platform could be an acquisition or public market valuation in the hundreds of millions to low billions of dollars, should it capture a meaningful portion of the synbio tools market. This is a scenario-dependent outcome, not a forecast, but it illustrates the scale of the prize for a company that successfully digitizes a critical, expensive, and manual step in a high-growth industry.
Data Accuracy: YELLOW -- The core product focus and market wedge are confirmed by multiple sources, but the specific growth catalysts and the existence of a data flywheel are inferred from the company's stated features and market context rather than directly evidenced by customer announcements.
Sources
PUBLIC
[Dealroom, retrieved 2026] New Wave Biotech - Dealroom | https://app.dealroom.co/companies/new_wave_biotech
[New Wave Biotech, retrieved 2026] DSP Decision Intelligence for Biomanufacturing | New Wave Biotech | https://www.newwavebiotech.com/
[AI Market Watch, Oct 2024] AI Market Watch LinkedIn Post | https://www.linkedin.com/posts/ai-market-watch_new-wave-biotech-ai-powered-bioprocess-activity-7279205662469840896-zjer
[The Org, retrieved 2026] New Wave Biotech | https://www.theorg.com/org/new-wave-biotech
[EU-Startups, Dec 2024] New Wave Biotech raises €1.2 million to transform R&D in synbio and alt protein production | EU-Startups | https://www.eu-startups.com/2024/12/new-wave-biotech-raises-e1-2-million-to-transform-rd-in-synbio-and-alt-protein-production/
[CB Insights, retrieved 2026] New Wave Biotech - CB Insights | https://www.cbinsights.com/company/new-wave-biotech
[Crunchbase, retrieved 2026] New Wave Biotech - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/new-wave-biotech
[GFI, retrieved 2026] New Wave Biotech - GFI Ecosystem | https://ecosystem.gfi.org/company/new-wave-biotech/
[Green Queen, retrieved 2026] New Wave Biotech Secures €1.2 Million in Latest Funding Round to Expand AI Bioprocess Simulation Platform - Cultivated X | https://cultivated-x.com/investments-finance/new-wave-biotech-secures-e1-2-million-latest-funding-round-expand-ai-bioprocess-simulation-platform/
Articles about New Wave Biotech
- New Wave Biotech's AI Simulator Aims to Cut 92% of Lab Experiments for Fermentation — The London startup has secured €1.2 million to optimize downstream processing, a notorious bottleneck for scaling alternative proteins and biochemicals.